Search

GA in Practice Background

Editorial Feature:

GA in Practice

How data and personal experience are evolving the treatment of geographic atrophy.

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Show Description +

Should treatment of geographic atrophy pause when a monocular patient develops wet AMD in their only seeing eye? In this episode of GA in Practice, Carl Danzig, MD, presents a real-world case to panelists Geeta Lalwani, MD, and Murtaza Adam, MD. The discussion turns to balancing anti-VEGF and complement inhibition therapy on a fixed alternating schedule, along with the access-to-care barriers facing patients who travel long distances for treatment.

Posted: 7/01/2026

Keywords:

Geographic Atrophy (GA)

•

complement inhibition

•

monocular

•

Choroidal Neovascularization, CNV

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Macular Degeneration

•

Anti-VEGF

•

patient access

•

barrier

Up Next

Multimodal Imaging for Biomarker Detection in GA Patients

Multimodal Imaging for Biomarker Detection in GA Patients

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Talking to Patients About Treatment Risks

Talking to Patients About Treatment Risks

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

GA in the Presence of Dense Cataract, Followed by CNV Development

GA in the Presence of Dense Cataract, Followed by CNV Development

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Delayed Complement Inhibition Therapy per Patient Request

Delayed Complement Inhibition Therapy per Patient Request

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Back to All Videos

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Should treatment of geographic atrophy pause when a monocular patient develops wet AMD in their only seeing eye? In this episode of GA in Practice, Carl Danzig, MD, presents a real-world case to panelists Geeta Lalwani, MD, and Murtaza Adam, MD. The discussion turns to balancing anti-VEGF and complement inhibition therapy on a fixed alternating schedule, along with the access-to-care barriers facing patients who travel long distances for treatment.

Posted: 7/01/2026

Keywords:

Geographic Atrophy (GA)

•

complement inhibition

•

monocular

•

Choroidal Neovascularization, CNV

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Macular Degeneration

•

Anti-VEGF

•

patient access

•

barrier

Please log in to leave a comment.